Developing E-Plasters to enable self-management of rapid and complete wound healing

开发电子膏药以实现伤口快速、完全愈合的自我管理

• 批准号: 10045492
• 金额: $ 6.37万
• 依托单位: NUTISSU LTD
• 依托单位国家: 英国
• 项目类别: Grant for R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10045492
• 关键词: Developing; Plasters; enable; self; management

Efficacious wound healing is a huge unmet clinical need. Wounds pose a significant economic cost to the healthcare system, and the society, but the impact often under-recognised.International Diabetes Federation shows, more than 460 million people are living with diabetes worldwide and by 2045 this number is expected to rise to 700 million. Diabetic foot ulcers usually turn out to be infectious and at times patient may end up with amputations. Yet, wounds can often lack priority, and investment.Wounds are not considered a disease, and chronic wound patients are assigned to long term wound management, and just "live with it" as therapies exist that slow down the advancement of wounds, but rarely reverse completely the problem.Thus there is a real need to address this.We aim to enable a better quality of life and facilitate significant cost savings to the NHS through our innovations based on biomaterials and biolectricity.This project will enable us to develop E-plaster(r), to enable self-management of chronic wounds using personalised, intuitive, patient centric therapy to rapidly and completely heal chronic wounds, and to ensure that acute wounds heal rapidly without acquiring complications.

有效的伤口愈合是一个巨大的未满足的临床需求。伤口给医疗系统和社会带来了巨大的经济成本，但其影响往往被低估。国际糖尿病联合会显示，全球有超过4.6亿人患有糖尿病，到2045年，这一数字预计将上升到7亿。糖尿病足溃疡通常是传染性的，有时病人可能最终截肢。然而，伤口往往缺乏优先考虑和投资。伤口不被认为是一种疾病，慢性伤口患者被分配到长期伤口管理，只是“忍受它”，因为存在减缓伤口进展的疗法，但很少能完全扭转这个问题。因此，我们有真实的需要解决这个问题。我们的目标是通过以下措施提高生活质量，并为国民保健服务节省大量成本我们的创新基于生物材料和生物电性。该项目将使我们能够开发E-plaster（r），使用个性化，直观，以患者为中心的治疗方法实现慢性伤口的自我管理，以快速完全治愈慢性伤口，并确保急性伤口快速愈合而不会出现并发症。